Your browser doesn't support javascript.
loading
Considerably decreased risk of cardiovascular disease with combined reductions in HbA1c, blood pressure and blood lipids in type 2 diabetes: Report from the Swedish National Diabetes Register.
Eeg-Olofsson, Katarina; Zethelius, Björn; Gudbjörnsdottir, Soffia; Eliasson, Björn; Svensson, Ann-Marie; Cederholm, Jan.
Afiliação
  • Eeg-Olofsson K; Department of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
  • Zethelius B; Geriatrics, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden Medical Products Agency, Uppsala, Sweden.
  • Gudbjörnsdottir S; Department of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
  • Eliasson B; Department of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
  • Svensson AM; Department of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
  • Cederholm J; Family Medicine and Preventive Medicine, Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden jan.cederholm@pubcare.uu.se.
Diab Vasc Dis Res ; 13(4): 268-77, 2016 07.
Article em En | MEDLINE | ID: mdl-27190080
ABSTRACT

OBJECTIVES:

Assess the effect of risk factors changes on risk for cardiovascular disease and mortality in patients with type 2 diabetes selected from the Swedish National Diabetes Register.

METHODS:

Observational study of 13,477 females and males aged 30-75 years, with baseline HbA1c 41-67 mmol/mol, systolic blood pressure 122-154 mmHg and ratio non-HDLHDL 1.7-4.1, followed for mean 6.5 years until 2012. Four groups were created a reference group (n = 6757) with increasing final versus baseline HbA1c, systolic blood pressure and non-HDLHDL cholesterol during the study period, and three groups with decreasing HbA1c (n = 1925), HbA1c and systolic blood pressure (n = 2050) or HbA1c and systolic blood pressure and non-HDLHDL (n = 2745).

RESULTS:

Relative risk reduction for fatal/nonfatal cardiovascular disease was 35% with decrease in HbA1c only (mean 6 to final 49 mmol/mol), 56% with decrease in HbA1c and systolic blood pressure (mean 12 to final 128 mmHg) and 75% with combined decreases in HbA1c, systolic blood pressure and non-HDLHDL (mean 0.8 to final 2.1), all p < 0.001 adjusting for clinical characteristics, other risk factors, treatments and previous cardiovascular disease. Similar risk reductions were found for fatal/nonfatal coronary heart disease, fatal cardiovascular disease, all-cause mortality and also in a subgroup of 3038 patients with albuminuria.

CONCLUSION:

Considerable risk reductions for cardiovascular disease and mortality were seen with combined long-term risk factor improvement.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pressão Sanguínea / Hemoglobinas Glicadas / Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Dislipidemias / Hipertensão / Lipídeos Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pressão Sanguínea / Hemoglobinas Glicadas / Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Dislipidemias / Hipertensão / Lipídeos Idioma: En Ano de publicação: 2016 Tipo de documento: Article